A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer. READ MORE

News

A recent study compared the effects of the standard of care alone versus combining the standard treatment with a TKI for patients with recurrent epithelial ovarian cancer.

READ MORE

Although Lynch syndrome is thought to increase the risk of colorectal and/or uterine cancer, certain mutations may confer an increased risk of breast or ovarian cancer.

READ MORE